O	0	3	The
O	4	10	effect
O	11	13	of
O	14	18	body
O	19	23	mass
O	24	29	index
O	30	32	on
O	33	40	overall
O	41	44	and
O	45	52	disease
O	52	53	-
O	53	57	free
O	58	66	survival
O	68	70	in
B-eligibility	71	75	node
I-eligibility	75	76	-
I-eligibility	76	84	positive
I-eligibility	85	91	breast
I-eligibility	92	98	cancer
I-eligibility	99	107	patients
I-eligibility	108	115	treated
I-eligibility	116	120	with
I-eligibility	121	130	docetaxel
I-eligibility	132	135	and
I-eligibility	136	147	doxorubicin
I-eligibility	147	148	-
I-eligibility	148	158	containing
I-eligibility	159	167	adjuvant
I-eligibility	168	180	chemotherapy
O	180	181	:
O	183	186	the
O	187	197	experience
O	198	200	of
O	201	204	the
O	205	208	BIG
O	209	211	02
O	211	212	-
O	212	214	98
O	215	220	trial
O	220	221	.

O	222	229	Obesity
O	230	233	has
O	234	238	been
O	239	244	shown
O	245	247	to
O	248	250	be
O	251	253	an
O	254	263	indicator
O	264	266	of
O	267	271	poor
O	272	281	prognosis
O	282	285	for
O	286	294	patients
O	295	299	with
O	300	307	primary
O	308	314	breast
O	315	321	cancer
O	322	323	(
O	323	325	BC
O	325	326	)
O	327	337	regardless
O	338	340	of
O	341	344	the
O	345	348	use
O	349	351	of
O	352	360	adjuvant
O	361	369	systemic
O	370	377	therapy
O	377	378	.

O	379	383	This
O	384	386	is
O	387	388	a
O	389	402	retrospective
O	403	411	analysis
O	412	414	of
B-total-participants	415	416	2
I-total-participants	416	417	,
I-total-participants	417	420	887
O	421	425	node
O	425	426	-
O	426	434	positive
O	435	437	BC
O	438	446	patients
O	447	455	enrolled
O	456	458	in
O	459	462	the
O	463	466	BIG
O	467	469	02
O	469	470	-
O	470	472	98
O	473	481	adjuvant
O	482	487	study
O	487	488	,
O	489	490	a
O	491	501	randomised
O	502	507	phase
O	508	511	III
O	512	517	trial
O	518	523	whose
O	524	531	primary
O	532	541	objective
O	542	545	was
O	546	548	to
O	549	557	evaluate
O	558	565	disease
O	565	566	-
O	566	570	free
O	571	579	survival
O	580	581	(
O	581	584	DFS
O	584	585	)
O	586	588	by
O	589	595	adding
O	596	605	docetaxel
O	606	608	to
O	609	620	doxorubicin
O	620	621	-
O	621	626	based
O	627	639	chemotherapy
O	639	640	.

O	641	643	In
O	644	647	the
O	648	655	current
O	656	664	analysis
O	664	665	,
O	666	669	the
O	670	676	effect
O	677	679	of
O	680	684	body
O	685	689	mass
O	690	695	index
O	696	697	(
O	697	700	BMI
O	700	701	)
O	702	704	on
O	705	708	DFS
O	709	712	and
O	713	720	overall
O	721	729	survival
O	730	731	(
O	731	733	OS
O	733	734	)
O	735	738	was
O	739	747	assessed
O	747	748	.

O	749	752	BMI
O	753	756	was
O	757	765	obtained
O	766	772	before
O	773	776	the
O	777	782	first
O	783	788	cycle
O	789	791	of
O	792	804	chemotherapy
O	804	805	.

O	806	813	Obesity
O	814	817	was
O	818	825	defined
O	826	828	as
O	829	830	a
O	831	834	BMI
O	835	836	>
O	836	838	or
O	838	839	=
O	840	842	30
O	843	845	kg
O	845	846	/
O	846	848	m2
O	848	849	.

O	850	852	In
O	853	858	total
O	858	859	,
B-intervention-participants	860	863	547
O	864	865	(
O	865	867	19
O	867	868	%
O	868	869	)
O	870	878	patients
O	879	883	were
B-intervention	884	889	obese
O	890	892	at
O	893	901	baseline
O	901	902	,
O	903	908	while
B-control-participants	909	910	2
I-control-participants	910	911	,
I-control-participants	911	914	340
O	915	916	(
O	916	918	81
O	918	919	%
O	919	920	)
O	921	929	patients
O	930	934	were
B-control	935	938	non
I-control	938	939	-
I-control	939	944	obese
O	944	945	.

O	946	955	Estimated
B-outcome	956	957	5
I-outcome	957	958	-
I-outcome	958	962	year
I-outcome	963	965	OS
O	966	969	was
B-cv-bin-percent	970	972	87
I-cv-bin-percent	972	973	.
I-cv-bin-percent	973	974	5
I-cv-bin-percent	974	975	%
O	976	979	for
O	980	983	non
O	983	984	-
O	984	989	obese
O	990	993	and
B-iv-bin-percent	994	996	82
I-iv-bin-percent	996	997	.
I-iv-bin-percent	997	998	9
I-iv-bin-percent	998	999	%
O	1000	1003	for
O	1004	1009	obese
O	1010	1018	patients
O	1019	1020	(
O	1020	1022	HR
O	1023	1024	1
O	1024	1025	.
O	1025	1027	34
O	1027	1028	;
O	1029	1030	P
O	1031	1032	=
O	1033	1034	0
O	1034	1035	.
O	1035	1038	013
O	1038	1039	)
O	1039	1040	.

O	1041	1050	Estimated
B-outcome	1051	1052	5
I-outcome	1052	1053	-
I-outcome	1053	1058	years
I-outcome	1059	1062	DFS
O	1063	1066	was
B-cv-bin-percent	1067	1069	75
I-cv-bin-percent	1069	1070	.
I-cv-bin-percent	1070	1071	9
I-cv-bin-percent	1071	1072	%
O	1073	1076	for
O	1077	1085	nonobese
O	1086	1089	and
B-iv-bin-percent	1090	1092	70
I-iv-bin-percent	1092	1093	.
I-iv-bin-percent	1093	1094	0
I-iv-bin-percent	1094	1095	%
O	1096	1099	for
O	1100	1105	obese
O	1106	1114	patients
O	1115	1116	(
O	1116	1118	HR
O	1119	1120	1
O	1120	1121	.
O	1121	1123	20
O	1123	1124	;
O	1125	1126	P
O	1127	1128	=
O	1129	1130	0
O	1130	1131	.
O	1131	1134	041
O	1134	1135	)
O	1135	1136	.

O	1137	1140	Ina
O	1141	1153	multivariate
O	1154	1159	model
O	1159	1160	,
O	1161	1168	obesity
O	1169	1177	remained
O	1178	1180	an
O	1181	1192	independent
O	1193	1203	prognostic
O	1204	1210	factor
O	1211	1214	for
O	1215	1217	OS
O	1218	1221	and
O	1222	1225	DFS
O	1225	1226	.

O	1227	1229	In
O	1230	1234	this
O	1235	1240	study
O	1240	1241	,
O	1241	1248	obesity
O	1249	1252	was
O	1253	1263	associated
O	1264	1268	with
O	1269	1275	poorer
O	1276	1283	outcome
O	1284	1286	in
O	1287	1291	node
O	1291	1292	-
O	1292	1300	positive
O	1301	1303	BC
O	1304	1312	patients
O	1312	1313	.

O	1314	1319	Given
O	1320	1323	the
O	1324	1334	increasing
O	1335	1345	prevalence
O	1346	1348	of
O	1349	1356	obesity
O	1357	1366	worldwide
O	1366	1367	,
O	1368	1372	more
O	1373	1381	research
O	1382	1384	on
O	1385	1394	improving
O	1395	1398	the
O	1399	1408	treatment
O	1409	1411	of
O	1412	1417	obese
O	1418	1420	BC
O	1421	1429	patients
O	1430	1432	is
O	1433	1439	needed
O	1439	1440	.
